Drugs / DPI-386
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05886660 | Jan 2022 → Sep 2024 | space motion sickness | Repurposed Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04947423 | Jun → Aug 2021 | motion sickness | Repurposed Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DPI-386 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04947423 ↗ |
| Route | Intranasal | “DPI-386 Nasal Gel” NCT04947423 ↗ |